Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors as Adjunct Therapy to Statins: A New Frontier in Cardiovascular Risk Reduction.

Autor: Lamia TH; Internal Medicine, Cox's Bazar Medical College, Cox's Bazar, BGD., Shah-Riar P; Internal Medicine, Doctors Hospital at Renaissance (DHR) Health, Edinburg, USA., Khanam M; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Khair F; Internal Medicine, Bangladesh Medical College, Dhaka, BGD., Sadat A; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Tania MK; Internal Medicine, Ibrahim Medical College and Birdem General Hospital, Dhaka, BGD., Haque SM; Internal Medicine, University of California, Riverside School of Medicine, Riverside, USA., Saaki SS; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Ferdausi A; Internal Medicine, Ibrahim Medical College, Dhaka, BGD., Naurin SA; Internal Medicine, Ibrahim Medical College, Dhaka, BGD., Tabassum M; Internal Medicine, Holy Family Red Crescent Medical College, Dhaka, BGD., Rahie RET; Internal Medicine, Dhaka Medical College and Hospital, Dhaka, BGD., Hasan R; Internal Medicine, Desert Valley Hospital, Victorville, USA.

Publikováno v: Cureus [Cureus] 2024 Oct 13; Vol. 16 (10), pp. e71365. Date of Electronic Publication: 2024 Oct 13 (Print Publication: 2024).